Cypress Prosorba Rheumatoid Arthritis Treatment Approvable - FDA Panel
This article was originally published in The Gray Sheet
Executive SummaryApproval of Cypress Bioscience's Prosorba immunoadsorption column should be limited to treatment of moderate to severe rheumatoid arthritis in patients who have failed disease-modifying anti-rheumatic drugs (DMARDs), FDA's Gastroenterology and Urology Devices Panel concluded at its Oct. 29 meeting in Rockville, Maryland.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.